Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.74% | 15.20% | 92.73% | 6,798.46% | 15,189.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.74% | 15.20% | 92.73% | 6,798.46% | 15,189.21% |
| Cost of Revenue | 14.08% | 22.08% | 80.64% | 585.04% | 765.73% |
| Gross Profit | 21.60% | 7.18% | 1,354.96% | 93.63% | 1,024.67% |
| SG&A Expenses | -13.99% | -12.15% | -4.72% | 39.92% | 41.53% |
| Depreciation & Amortization | 3.98% | -7.44% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.02% | 6.50% | 30.60% | 44.00% | 31.65% |
| Operating Income | 15.15% | -0.78% | -11.64% | -2.97% | 28.60% |
| Income Before Tax | 6.86% | -10.11% | -11.27% | -3.16% | 34.82% |
| Income Tax Expenses | -88.19% | -58.22% | 236.35% | -30.54% | 188.57% |
| Earnings from Continuing Operations | 8.47% | -9.23% | -14.99% | -2.82% | 32.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.47% | -9.23% | -14.99% | -2.82% | 32.50% |
| EBIT | 15.15% | -0.78% | -11.64% | -2.97% | 28.60% |
| EBITDA | 12.46% | 0.62% | -12.06% | -2.65% | 36.56% |
| EPS Basic | 31.43% | 9.00% | 2.08% | 15.22% | 43.33% |
| Normalized Basic EPS | 34.27% | 13.29% | 5.27% | 15.11% | 47.45% |
| EPS Diluted | 31.43% | 9.00% | 2.08% | 15.22% | 43.33% |
| Normalized Diluted EPS | 34.27% | 13.29% | 5.27% | 15.11% | 47.45% |
| Average Basic Shares Outstanding | 33.48% | 20.04% | 17.45% | 21.28% | 19.12% |
| Average Diluted Shares Outstanding | 33.48% | 20.04% | 17.45% | 21.28% | 19.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |